Twinbeech Capital LP purchased a new stake in Novavax, Inc. (NASDAQ:NVAX - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 69,034 shares of the biopharmaceutical company's stock, valued at approximately $555,000.
Several other hedge funds also recently made changes to their positions in the stock. Vanguard Group Inc. grew its position in Novavax by 1.9% during the fourth quarter. Vanguard Group Inc. now owns 15,726,250 shares of the biopharmaceutical company's stock worth $126,439,000 after buying an additional 296,181 shares in the last quarter. Shah Capital Management raised its position in Novavax by 13.6% during the 4th quarter. Shah Capital Management now owns 11,148,846 shares of the biopharmaceutical company's stock valued at $89,637,000 after purchasing an additional 1,333,305 shares during the last quarter. Sanofi bought a new position in Novavax during the 4th quarter valued at approximately $55,319,000. Geode Capital Management LLC grew its holdings in shares of Novavax by 4.4% during the 4th quarter. Geode Capital Management LLC now owns 3,657,695 shares of the biopharmaceutical company's stock worth $29,415,000 after acquiring an additional 155,206 shares during the period. Finally, Deep Track Capital LP purchased a new position in shares of Novavax during the 4th quarter worth approximately $16,080,000. 53.04% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Several analysts recently weighed in on NVAX shares. TD Cowen upgraded Novavax to a "hold" rating in a research note on Thursday, February 27th. B. Riley reiterated a "buy" rating on shares of Novavax in a research note on Monday, May 19th. JPMorgan Chase & Co. cut their target price on Novavax from $9.00 to $7.00 and set an "underweight" rating on the stock in a research note on Friday, May 9th. Finally, BTIG Research assumed coverage on Novavax in a research note on Friday, February 28th. They set a "buy" rating and a $19.00 target price on the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $19.00.
Check Out Our Latest Research Report on NVAX
Novavax Stock Performance
Shares of NASDAQ NVAX traded down $0.23 during midday trading on Wednesday, hitting $7.16. 2,172,476 shares of the stock traded hands, compared to its average volume of 7,253,038. The firm has a 50-day moving average of $6.60 and a two-hundred day moving average of $7.80. The firm has a market capitalization of $1.16 billion, a P/E ratio of -3.17, a PEG ratio of 2.85 and a beta of 3.21. Novavax, Inc. has a one year low of $5.01 and a one year high of $23.86.
Novavax (NASDAQ:NVAX - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported $2.93 earnings per share for the quarter, beating the consensus estimate of $0.71 by $2.22. The firm had revenue of $666.66 million for the quarter, compared to the consensus estimate of $204.08 million. Novavax's quarterly revenue was up 610.3% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.05) earnings per share. Equities analysts forecast that Novavax, Inc. will post -1.46 earnings per share for the current fiscal year.
About Novavax
(
Free Report)
Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.
Featured Stories

Before you consider Novavax, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novavax wasn't on the list.
While Novavax currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.